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Abstract (149 words) 
Our understanding of the mechanisms underlying HLA associations with inflammatory arthritis 
continues to evolve. Disease associations have been refined, and interactions of HLA genotype with 
other genes and environmental risk factors in determining disease risk have been identified. This 
Review provides basic information on the genetics and molecular function of HLA molecules, as well as 
general features of HLA associations with disease. We summarise evidence for various peptide-
dependent and peptide-independent mechanisms by which HLA alleles might contribute to the 
pathogenesis of three types of inflammatory arthritis: rheumatoid arthritis, spondyloarthritis and 
systemic juvenile idiopathic arthritis. Also discussed are HLA allelic associations that shed light on the 
genetic heterogeneity of inflammatory arthritides and on the relationships between adult and 
pediatric forms of arthritis. Clinical implications range from improved diagnosis and outcome 
prediction to the possibility of using HLA associations in developing personalized strategies for the 
treatment and prevention of these diseases.  
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[H1] Introduction 
Highly variable human leukocyte antigen (HLA) genes were first discovered in the 1950s; they were 
recognized as important effectors of transplant rejection and immune responses to specific antigens, 
following pioneering studies on their murine homologs in the H2 gene region (Box 1 and refs. 
therein). Across species, this gene region is referred to as the major histocompatibility complex (MHC). 
The identification of HLA genes led to their intense investigation as inherited risk factors for 
conditions linked with autoimmunity, including rheumatic diseases. Among the earliest findings were 
the associations of HLA-B27 serotype (related to HLA-B*27 genotype, see Box 1 for nomenclature) 
with ankylosing spondylitis (AS)1,2 and other spondyloarthritides (SpA), a group of arthritides with 
characteristic involvement of the spine, including psoriatic arthritis, inflammatory bowel disease (IBD) 
with SpA, and reactive arthritis as well as AS3,4(Table 1). Similarly, early studies identified 
associations of HLA-DR4 serotype (related to HLA-DRB1*04 genotype) and other HLA-DR alleles 
(which contain similar sequences at positions 70-74 of the subunit, the ‘shared epitope’ or SE)5,6 
with rheumatoid arthritis (RA; Table 1). These associations have been replicated extensively and 
refined using genome-wide association study (GWAS) data (reviewed in 7,89). HLA associations with 
many other rheumatic diseases have been identified, including, for example, systemic sclerosis10, 
inflammatory myositis11, and systemic lupus erythematosus (SLE)12. In general, different diseases are 
associated with different alleles of different HLA genes, although some alleles are associated with 
more than one disease. 
The current paradigm for the pathogenesis of HLA-associated diseases holds that both genetic 
predisposition and environmental triggers contribute to disease development. HLA genes typically 
make the largest individual genetic contribution to inherited disease susceptibility, whether judged by 
the degree of confidence in the disease associations (extremely low P values) or by the magnitude of 
their effects on disease risk (high odds ratios)13,14. However, these genes are thought to account for 
substantially less than half of the full genetic burden15,16, the remainder being attributed to polygenic 
influences and, as yet, incompletely mapped17-19. Disease occurrence among genetically susceptible 
individuals (penetrance) is typically low, reflecting risk modification by hormones, environmental 
factors (for example, infection, microbiota, lifestyle and diet), and stochastic effects on the formation of 
antigen receptor repertoires (such as in RA20). Moreover, the importance of any one genetic 
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contribution depends on the presence of other genetic factors (gene–gene interaction, also known as 
epistasis) or environmental factors (gene–environment interaction).  
In this Review, we discuss HLA associations with diseases primarily characterized by inflammation-
driven arthritis, such as RA, SpA and their pediatric counterparts. We also touch on other diseases in 
which inflammation-driven arthritis occurs, such as systemic sclerosis, SLE, dermatomyositis and 
systemic juvenile idiopathic arthritis (sJIA). We begin by describing the various HLA genes and 
functions of HLA molecules and summarize general features of HLA–disease associations. We present 
current hypotheses on the function of HLA risk alleles in disease etiology, focusing on RA and SpA, in 
which mechanistic understanding is arguably the most advanced, and sJIA, in which an HLA 
association has recently been identified. Finally, we consider the clinical implications of HLA 
associations for diagnosis, prognosis, definition of disease subtypes, therapy and prevention. 
 
[H1] HLA genes and molecules  
The genes coding for HLA proteins are located in a region on chromosome 6, interspersed between 
other genes involved in immune recognition and regulation (Box 1; Fig. 1). HLA proteins have 
peptide-binding domains and are expressed at the cell surface, allowing peptides to be presented for 
inspection by T cells via clonally diverse  T cell receptors (TCRs) (Fig. 2). Class I and class II HLA 
proteins are distinguishable, based on genomic location, expression, structure and function (Fig. 1; 
Fig. 2; Box 2). Class I HLA molecules primarily present peptides generated in the cytoplasm to 
cytolytic CD8+ T cells21 (Fig. 2a; Box 2). Class II HLA molecules bind peptides derived from endocytic 
processing, often after uptake from outside the cell, and present them to CD4+ T cells, which produce 
cytokines to regulate other immune cells (Fig. 2b; Box 2). The recognition of HLA-bound peptides by 
TCRs drives thymic selection and other tolerance mechanisms, as well as antigen-specific T-cell 
responses to infection and, in autoimmunity, to self proteins. 
Pathogen-driven selection and diversification of HLA genes during evolution has resulted in multiple 
HLA class I and class II genes, and multiple alleles at any one gene (see Box 1), such that most 
individuals are heterozygous at most HLA genes22,23. Much of the amino acid variation in HLA class I 
and class II alleles affects the shape and charge distribution within the peptide binding groove. These 
variations, in turn, control peptide side-chain preferences at important positions in the peptide 
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(‘anchor residues’), yielding distinct repertoires of self-peptides and non-self-peptides that bind to 
each allele24. Databases of HLA class I-binding peptides and class II-binding peptides are available (for 
example, the Immune Epitope Database and Analysis Resource)25, as are algorithms that predict 
peptide-binding preferences for HLA alleles26,27 (epitope prediction software for MHC class I and class 
II molecules). 
 
[H1] HLA associations with disease  
Many investigations of HLA disease associations have been case-control studies, which compare the 
frequencies of HLA alleles between groups of healthy individuals and patients with a specific condition 
(for HLA typing methods, see Box 1). In many early studies, HLA association signals were broad and 
difficult to pinpoint, because genetic recombination events in the HLA gene region rarely occur outside 
of a small number of recombination hot spots22,28. Thus, clustered polymorphisms on the same 
chromosome are co-inherited as haplotypes, spanning a number of adjacent HLA genes (linkage 
disequilibrium)22,28. For example, particular HLA-DRB1 alleles are consistently accompanied by 
particular HLA-DQ alleles (which are closely linked as shown in Fig. 1), and some extended haplotypes 
span much of the HLA region29. Distinguishing the disease-related alleles within these haplotypes has 
been a big challenge in the field.  
The advent of high-density SNP arrays, which compare hundreds of thousands of single-nucleotide 
polymorphisms (SNPs) between thousands of patients and controls, has helped to overcome this 
problem9,30,31. Systematic procedures can resolve broad association signals and pinpoint the associated 
polymorphic sites at one or a few HLA gene loci19,30,32. These fine-mapped associations reflect 
polymorphisms at particular amino acid positions of HLA proteins and often modulate peptide 
interactions, although other interactions can also be affected. Many of these re-defined associations 
occur over diverse ethnic groups, updating an earlier impression that HLA associations tend to differ 
between ethnic groups7,33. In some instances, the associated sites are promoter polymorphisms that 
regulate expression levels of HLA class II molecules (for example, promoters of HLA-DRB1, DQA1 and 
DQB1 in systemic lupus erythematosus, or of HLA-DPB1 in systemic sclerosis)34,35 or the expression of 
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HLA region-encoded accessory proteins, which influence peptide loading (for example, in HLA-DOA in 
RA and in TAP2 in systemic sclerosis; see Figs. 1 and 2 and Box 2)35-37. 
HLA–disease associations can have gene dosage effects. Odds ratios are higher for homozogous than 
for heterozygous genotypes of risk alleles (for example, in associations of SE-containing DRB1 
alleles with both RA38 and rheumatoid factor (RF)-positive, polyarticular juvenile idiopathic 
arthritis (JIA)39, and in at least some studies of B*27 associations with AS40). In addition, in JIA, 
having an increased number of risk alleles has been correlated with a lower average age of disease 
onset41.  
HLA alleles associated with rheumatic diseases commonly confer increased risk of disease. Some HLA 
alleles, however, are less frequent in patients than in healthy individuals, implying that these alleles 
confer protection, either because they are less pathogenic than typical HLA alleles, or because they 
mediate an anti-inflammatory effect. For example, combined genetic, epidemiological and 
immunological evidence suggests a protective effect of HLA-DRB1*13 in RA (Table 1), systemic lupus 
erythematosus and systemic sclerosis (reviewed in 42). 
   
[H1] Mechanisms of HLA disease associations  
Different rheumatic diseases are associated with different HLA genes, suggesting that there is no 
unifying mechanism underpinning these associations. Conversely, as some HLA gene associations are 
shared for different diseases, some mechanistic features might also overlap. This idea is exemplified 
by the SpAs, all of which are associated with HLA-B*27(reviewed in 4). Indeed, the association of HLA-
B*27 with disease in adults, adolescents and children with SpA suggests similar underlying 
mechanisms across the age spectrum31. Likewise, the expression of SE-containing DRB1 alleles in both 
adults with RF-positive RA and pediatric patients with RF-positive polyarticular JIA suggests 
overlapping mechanisms43. In this section, we summarize the current data and concepts concerning 
the mechanisms of HLA association with RA, SpA, and systemic JIA (sJIA). 
 
[H2] Rheumatoid arthritis and the HLA-DRB1 alleles  
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RA is characterized by symmetrical, typically erosive polyarthritis affecting distal joints. Anti-
citrullinated protein (ACPA) and RF autoantibodies contribute to diagnosis, and their presence is 
associated with worse outcomes (as discussed further below)44. 
Twin studies indicate that this disease has a heritability of 53-68%, with little difference in heritability 
between ACPA-positive and ACPA-negative RA or between ethnic groups45-47. For ACPA-positive RA, 
the contribution of SE-containing HLA-DRB1 alleles explains ~20% of the genetic risk, but it accounts 
for only a small percentage of the genetic risk of ACPA-negative RA46. HLA gene associations with 
ACPA-negative RA are less extensively characterised, but associations with HLA-DRB1*03 and HLA-
B*08 have been identified48. 
 
[H3] Refinement of HLA associations with RA risk or protection  
 
The original shared epitope (SE) hypothesis identified a sequence motif (Q[K/R]RAA in single-letter 
code) spanning residues 70-74 of the HLA-DR  chain as the distinguishing feature of the RA-
associated HLA-DRB1 alleles known at the time (HLA-DRB1*01:01, *04:01, and *04:04 in current 
nomenclature; cf. Table 1)6. Structural studies showed that the SE influenced the side-chain 
preferences of a pocket (P4) in the peptide binding groove of HLA-DR and included both TCR and 
peptide contact residues in the -chain region flanking the bound peptide49 (Fig. 3a, left). An 
informative exception was a variant HLA-DR4 allele, HLA-DRB1*04:026, which is not associated with 
increased risk of RA50-52. DRB1*04:02 encodes the sequence 70-DERAA-74 in place of the SE sequence, 
reversing the charge at the P4 pocket6. This finding also suggested that HLA-DRB1, rather than a 
closely linked gene within the DRB1*04 haplotype, is the principal susceptibility locus50. Later studies 
identified additional SE-containing alleles (DRB1*04:05, *04:08,  *14:02, *10:01 and related others; 
Table 1) and revealed them to carry different levels of risk of RA, with HLA-DRB1*04:01 having the 
strongest association in patients with European ancestry38. In 2012, GWAS data identified a minimal 
set of single-nucleotide polymorphisms that explained the HLA association with RA32. This analysis 
confirmed the importance of residues K71 and A74 in the traditional SE of HLA-DRB1 in disease 
susceptibility and identified an even stronger contribution from residue 11 in the P4 pocket in the 
floor of the peptide binding site (Fig. 3a, left). These three residues explained all other association 
signals in the DRB1 gene, including residue 13, which is in linkage disequilibrium with residue 1132. 
8 
 
Independent RA associations with single amino acid polymorphisms in HLA-B and HLA-DPB1 were 
also identified 32. Similar patterns were found in an Asian RA cohort33.  
Similarly, studies of DRB1 variation have considered whether protection against RA accrues from the 
presence of specific DRB1 alleles, such as DRB1*13 42,52(Table 1) or DRB1*04:02 50, or, rather, with the 
presence of particular sequence motifs, such as 70-DERAA-74 in place of the SE, or the presence of 
single amino acid polymorphisms, such as I67 or D70 53,54. This is not fully resolved. 
Interestingly, several family studies show an increased risk of developing RA in patients who lack 
DRB1 SE alleles themselves, but whose mothers have SE+ DR alleles – an influence of non-inherited 
maternal alleles (NIMA) (reviewed in55,56). Not all such studies confirm the NIMA effect, which is 
thought to relate to the ability of maternal cells to enter the fetal circulation and shape immune system 
development. The mechanistic implications remain unclear. 
 
[H3] Gene–environment interactions involving the shared epitope  
Epidemiologic studies of ACPA-positive RA have provided striking evidence for a gene–environment 
interaction: two environmental factors, smoking and gingivitis, increase the risk of RA, but only in 
carriers of SE-containing HLA-DRB1 alleles57-61. Both smoking and gingivitis induce protein 
citrullination, a post-translational modification of positively charged arginine residues to citrulline, 
which is catalyzed by peptidylarginine deiminases (PAD) (Fig. 3b)62. Smoking-induced inflammation 
upregulates host PAD enzymes in the lungs57. Porphyromonas gingivalis, a bacterium associated with 
gingivitis, has its own PAD enzyme; another gingivitis-associated pathogen, Aggregatibacter 
actinomycetemcomitans, produces a toxin that induces hypercitrullination of proteins in neutrophils 
and promotes their extracellular release60. This evidence suggests a model in which the SE confers risk 
of autoreactivity directed against citrullinated self-proteins, which are generated at sites of 
neutrophilic inflammation. The participating self-reactive lymphocytes and autoantibodies may then 
attack the joint. 
 
[H3] Neoantigen hypothesis 
An attractive hypothesis is that, in RA, citrullination can make some self-antigens appear to be non-
self, which can lead to the loss of self-tolerance (known as the neoantigen hypothesis). This hypothesis 
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might explain the association of ACPA-positive RA with the SE of HLA-DRB1, as citrullination 
differently affects the binding of some peptides to HLA-DR proteins with and without the SE (Fig. 3a, 
right). Studies of peptides derived from foreign antigens unrelated to RA provided evidence that the 
P4 pocket of the HLA-DR0401 protein accommodates neutral, polar or negative side chains, but is far 
less accommodating to positively-charged arginine residues63-65. This suggested that self peptides with 
arginine residues at position P4 (the residue that binds the P4 pocket) may not be presented under 
non-inflammatory conditions, when PAD is unavailable, and thus fail to induce tolerance. Citrullination 
of such arginyl side chains, which neutralizes their positive charges, occurs in inflammatory states 
when PAD is released by neutrophils57,60. At least some of the resulting P4-citrullinated self peptides 
acquire the ability to bind HLA-DR0401 molecules66,67. These citrullinated self peptides are then 
available to stimulate effector/memory CD4+ T helper cells, which are expanded in the circulation of 
patients with RA, compared to healthy individuals, whereas regulatory T cells cells are depleted67 (Fig. 
3a, right). This process probably enables B cells with surface immunoglobulin specific for citrullinated 
self-antigens to recruit T cell help and produce ACPAs. Crystallographic studies and binding assays 
evaluating the interaction of HLA-DR0401 protein with several P4-citrullinated self peptides confirm 
gains in binding following citrullination67,68. 
Studies with other shared epitope-containing HLA-DR variants and more peptides have shown, 
however, that the amount of binding gained from P4-citrullination is variable, and in several cases no 
gain is apparent, suggesting that the magnitude of the effect is context-dependent68,69. Citrullination at 
other anchor or non-anchor residues usually has no effect on (or weakens) binding68,70. Importantly, to 
support a neoantigen hypothesis, it is not necessary to postulate that all P4-citrullination events result 
in improved binding to shared epitope-containing HLA-DR alleles – the loss of tolerance to a small 
number of neoantigens might be enough to explain an increased disease risk. 
Similar considerations may answer the reverse question of why other HLA-DRB1 alleles have no 
association with ACPA-positive RA (Supp. Fig. 1). The RA-nonassociated HLA-DR4 variant protein, 
DR0402 (with its DRB1*04:02-encoded -chain harbouring the 70-DERAA-74 sequence in place of the 
SE), binds P4-citrullinated peptides, but unlike HLA-DR0401, this variant binds unmodified (P4-
arginine-containing) precursors almost as well, suggesting that the parent peptides are available to 
induce tolerance (Supp. Fig. 1a)67. The binding (or lack of binding) of self-peptides to other HLA-DR 
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alleles is presumably unaffected by citrullination of arginine residues (Supp. Fig. 1b), as apart from 
their different charges, arginine and citrulline are very similar in structure. Citrullination might also 
affect other aspects of antigen presentation in RA (for example, by modifying the proteolytic 
processing of self-proteins), but there is no known reason for these other aspects to select for SE-
containing HLA-DRB1 alleles67,71.  
Another mechanism has been proposed72 to explain the protective effects of HLA-DRB1*13 in ACPA-
positive RA, although confirmation is still needed. HLA-DRB1*13 encodes the DERAA sequence, as does 
HLA-DRB1*04:02, and the DR13 protein has been reported to be broken down into peptides with a 
DERAA core, which bind to HLA-DQ 72. These peptides induce T cell tolerance against homologous 
microbial peptides and citrullinated vinculin peptides, to which ACPA-positive patients with RA would 
otherwise mount pathogenic T cell responses. 
The discovery of anti-carbamylated protein (anti-CarP) autoantibodies in a subset of patients with RA 
has raised new questions about the mechanisms by which post-translational modifications break self 
tolerance. Carbamylation is a post-translational modification of lysine by cyanate, which is produced 
from thiocyanate by neutrophil myeloperoxidase during oxidative stress (Fig. 3b). Anti-CarP 
autoantibodies and ACPAs are not usually co-expressed in the same patients and do not seem to cross-
react with each other73. Anti-CarP antibodies are not associated with the shared epitope or with 
smoking74. The effect of lysine carbamylation on the presentation of self peptides by SE+ DR alleles has 
not been characterised, but when examined using foreign peptides, the SE does not seem to 
discriminate strongly against lysine at P4 63. As a result, the SE may not confer an allele-specific 
mechanism for breaking tolerance through gain of binding after carbamylation. This would explain the 
lack of SE association with anti-CarP autoantibodies. However, the mechanism by which 
carbamylation breaks self-tolerance remains unresolved. 
The neoantigen model is attractive because it accounts for the selective presence of ACPAs (but not 
anti-CarP autoantibodies) in patients with RA who carry shared epitope-containing HLA-DRB1 alleles; 
these alleles discriminate between certain non-binding parental peptides (containing arginine at P4) 
and post-translationally modified peptides (containing citrulline at P4). Notably, analogous 
mechanisms have been identified in celiac disease and in type 1 diabetes, wherein tissue 
transglutaminase creates neoantigens that bind to HLA-DQ risk alleles75,76.  
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[H3] Calreticulin signalling hypothesis 
Another mechanistic hypothesis to explain the association of SE-containing DRB1 alleles with RA 
proposes that the SE region of the HLA-DR  chain provides a ligand for cell signalling that other HLA-
DRB1 alleles lack, by interaction with calreticulin (Supp. Fig. 2a). Calreticulin was discovered as a 
calcium-binding protein that chaperones nascent glycoproteins in the ER; its translocation to the 
plasma membrane of damaged cells activates phagocytosis77. SE-containing peptides or intact SE-
containing HLA-DR molecules bind calreticulin78, which stimulates proinflammatory changes, such as 
nitric oxide production, in antigen-presenting cells (APCs), in a CD91-dependent fashion79. The same 
interaction has been proposed to explain how, in CD8-CD11c+ dendritic cells, SE-containing peptides 
trigger the production of IL-6 and IL-23, which activate TH17 cells, whereas in CD8+CD11c+ dendritic 
cells the same stimulus inhibits the production of indoleamine 2,3 dioxygenase (IDO), an enzyme 
important in regulatory T-cell activation80. A cyclised SE-containing peptide has been shown to bind 
calreticulin, enhance osteoclast differentiation and activation in vitro, and exacerbate bone erosion in 
murine arthritis81; these processes could contribute to erosive disease in RA patients with SE-
containing DRB1 alleles82. Intriguingly, citrullination of calreticulin increases its affinity for the shared 
epitope, providing a link between the shared epitope and environmental factors known to increase the 
risk of erosive RA83. However, these SE-linked innate immune effects do not account for specific 
autoimmunity against citrullinated self antigens. 
 
[H3] Low CLIP affinity hypothesis  
Another mechanistic hypothesis derives from the observation that SE-containing HLA-DR molecules 
have a low affinity for class II-associated invariant chain peptides (CLIP), the nested set of invariant 
chain (Ii) fragments that occupy the peptide binding groove prior to the exchange for endosomal 
peptides during HLA class II–peptide complex assembly (Fig. 2b)84. For most HLA class II alleles, 
efficient peptide exchange requires catalysis of peptide release by the accessory molecule HLA-DM 
(Fig. 2b), but alleles with a lower affinity for CLIP, such as HLA-DR0401, can release CLIP 
spontaneously and might load peptides without the participation of HLA-DM85 (Supp. Fig. 2b). As 
HLA-DM selects for a stably bound peptide repertoire, HLA-DR protein variants with low CLIP affinity 
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may acquire less stably bound peptides; indeed, these proteins have been shown to undergo increased 
peptide exchange at the cell surface85. This may influence loss of self-tolerance; for example, at sites of 
inflammation, extracellular proteases generate peptides (neoepitopes) that can be presented by HLA 
molecules owing to peptide exchange at the surface of APCs. The spontaneous release of CLIP and 
subsequent loading of weakly-bound peptides are also associated with a faster turnover of HLA class II 
molecules, leading to lower surface expression, which could impair central and peripheral tolerance 
mechanisms86.  
Whether low CLIP affinity is relevant to the contribution of the DRB1 SE to RA susceptibility remains 
unclear, but some evidence implicates this mechanism in other HLA associations. A HLA-DPB1 
polymorphism (Gly84) impairs the folding of the CLIP region of Ii into the peptide-binding groove 87. 
This impairment enables endosomal peptide loading of HLA-DP without HLA-DM editing (Supp. Fig. 
2b) 88, as well as premature loading with TAP-transported peptides in the endoplasmic reticulum 
(ER)89. Intriguingly, this polymorphism has been associated with susceptibility to ACPA-positive RA 
(and other diseases) in Japanese individuals (Table 1)37. Moreover, in the nonobese diabetic mouse 
model of type 1 diabetes, mutagenesis of CLIP to strengthen its binding to another low CLIP-affinity 
class II allele protects against disease90.  
 
[H3] Influence of the shared epitope on microbiota 
The intestinal microbiota are known to affect immune regulation and autoimmunity, and HLA genes 
might, in turn, influence the composition of the intestinal microbiota. For example, compared to 
healthy individuals, the abundance of Prevotella copri was increased in the intestines of patients with 
new-onset RA, but not in patients with established RA. Even though the abundance of P. copri was 
influenced by HLA genes, this bacterium was most abundant in patients without SE-containing DRB1 
alleles91, arguing against a mechanism whereby the SE-containing risk alleles select arthritogenic 
microbiota. In HLA-DR4-transgenic mice, expression of shared epitope-containing alleles is associated 
with increased intestinal permeability, complex alterations in microbial composition, and the 
intestinal expression of type 17 cytokines92, but the relevance of these findings to RA remains unclear. 
 
[H2] Spondyloarthritis and HLA-B*27  
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The SpAs share associations of varying strength (greatest for AS) with HLA-B*27:05 and other HLA-
B*27 subtypes, of which over 100 have been identified, though only the more prevalent subtypes have 
been examined for disease associations (Table 1)93. SpA characteristically affects the spine and 
sacroiliac joints; other clinical features include extra-articular enthesitis, peripheral arthritis 
(particularly in the lower limbs) and osteitis94. The expression of HLA-B*27:05 in rats and mice causes 
joint pathology with some features of SpA95. Disease manifestations in HLA-B*27 transgenic rats 
include destructive arthritis, enthesitis, spondylitis and ankylosis, which resembles human disease 
more closely than the disease in HLA-B*27 transgenic mice95. Data from an early twin study indicated 
that although AS risk is mostly controlled by genetic rather than environmental variation, HLA-B*27 
genotype contributes less than half of the heritable component96. More recently, researchers reported 
that HLA-B*27 contributes 20.1% of the heritability of AS, and identified other genes that could explain 
4.3% of the heritability, although the majority of the genetic heritability remained unexplained19. A 
GWAS identified additional AS-associated genes14, including the gene that encodes endoplasmic 
reticulum aminopeptidase 1 (ERAP1), which mediates N-terminal trimming of class I-bound peptides 
in the ER during HLA class I peptide loading14. Alleles of ERAP1 that confer reduced enzymatic activity 
against certain peptide substrates have been reported to be protective against AS97-99.  
Notably, polymorphisms in ERAP1 are only linked to AS in patients who express HLA-B*27 36 or HLA-
B*40 30 (another AS risk allele; Table 1) and not in patients who express other HLA-B alleles. This 
epistatic (gene/gene) interaction suggests that ERAP1 contributes to disease susceptibility by 
exacerbating the pathogenic role of HLA-B*27. Another epistatic interaction results in a greater risk 
for developing AS in patients heterozygous for two HLA class I risk alleles (HLA-B*27 and HLA-
B*40:01, the latter encoding the Bw60 serotype) than would be expected from the additive effect of 
the two alleles on disease risk 100,101.  
Additional AS-associated variants at genes such as the IL23 receptor, IL1 receptor type II and T cell 
transcription factors increase the propensity for pro-inflammatory signalling by the TH17-promoting 
cytokines, IL-1 and IL-2314. These findings are consistent with data from immunological studies and 
clinical trials implicating Th17 and other IL-17-secreting cells in SpA102.  
In SpA, inflammation of the sacroiliac and intervertebral joints is associated with both erosive bone 
changes and new bone formation at the entheses. HLA-B27 does not directly affect bone formation in 
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transgenic mice or osteoblast differentiation by mouse or human bone precursor cells in vitro 80; 
rather, epigenetic and gene expression analyses suggest that new bone formation occurs in SpA owing 
to HLA-B27-driven inflammation103,104. The mechanistic hypotheses proposed to account for these 
findings are depicted in Fig. 4a and explained in the remainder of this section.  
 
[H3] Arthritogenic peptide hypothesis 
A possible source of HLA-B27-driven inflammation in SpA is the presentation of pathogen-derived, 
‘arthritogenic’ peptides (that is, exogenous peptides that are sufficiently similar to self-antigens to 
incite autoimmunity) to CD8+ T cells and the resulting selection of high affinity autoreactive T cells 
(similar to the high-affinity T-cell selection that occurs during repeated antigen presentation in 
chronic infections105). T cells that recognize HLA-B27-bound candidate arthritogenic peptides from 
intracellular bacteria have been identified in patients with reactive arthritis106. A link between peptide 
presentation and disease could result from differences in features of peptides bound to disease-
associated versus non-associated HLA-B27 alleles107-110, of which presentation by the former could 
lead to the selection of autoreactive T cells. However, no qualitative differences between peptides that 
can bind these allelic groups have been identified111. Nonetheless, consistent with an antigen-driven 
process, oligoclonal T cell expansions are present in the blood and at sites of inflammation in patients 
with SpA112-114. Interestingly, joint-infiltrating CD8+ T cells that, unusually, produce IL-17 have been 
detected in patients with PsA115. Indeed, arthritis risk in psoriasis patients has been linked to HLA-
B*27, specifically glutamic acid at position 45116 and asparagine at position 97117 , both of which are 
located in the peptide-binding groove and likely to influence peptide presentation (Fig. 4b)118. 
However, in transgenic rats with high copy numbers of the HLA-B27 transgene, CD8+ T cells are not 
required for the development of arthritis and intestinal disease 119. This finding, together with the low 
frequencies of self-reactive or cross-reactive CD8+ T cells in patients with other SpAs, such as AS, and 
the apparent function of TH17 cell-derived cytokines in SpA (see above102), suggests that HLA-B27-
restricted CD8+ T cell involvement cannot fully account for SpA. However, failure to control the activity 
of high avidity autoreactive CD8+T cells could contribute to pathogenesis in some types of SpA, such as 
reactive arthritis and PsA. 
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[H3] Cell surface open conformations of HLA-B27  
Another mechanistic hypothesis to explain the association of HLA-B*27 alleles with SpAs is based on 
the fact that a free cysteine (Cys67; Fig. 4b) (and perhaps other cysteines)120 in HLA-B27 heavy chains 
promotes the formation of peptide-free, open conformations of HLA-B27 heavy chains  (including 
dimers and possibly other forms), which do not include 2-microglobulin. Such open conformations 
are expressed at the cell surface and participate in pathogenic immune signalling (Fig. 4a)121-123. Cell 
surface HLA-B27 open conformations are generated from unstable peptide–B27 complexes during 
HLA class I recycling121. Cys67-dependent HLA-B27 homodimer formation has been detected on the 
cell surface of transfected B cell lines and SpA patient and HLA-B*27 transgenic rat 
monocytes121,122,124,125. Furthermore, in addition to HLA-B27 homodimers, HLA-B27 could also 
dimerize or oligomerize with other cell surface molecules, such as HLA-F, which binds to 
disassembling HLA-class I molecules121,126. Unique molecular features of HLA-B27, including Cys67, 
could promote the formation of free class I heavy chains; during class I recycling, cell surface HLA-B27 
open conformations are generated from unstable peptide–B27 complexes121,125. The expression of 
such conformations is increased on cells in the inflamed intestine and joints of patients with SpA 
124,127,128. Additionally, in a HLA-B*27 transgenic rat model of arthritis, the expression of open 
conformations of HLA-B27 on immune cells increases with disease progression125.  
The enzymes ERAP1 and ERAP2 trim peptides and control the supply of appropriately-sized peptides 
for class I binding, thus controlling the rate of formation of cell surface peptide–HLA-B27 complexes 
(Fig. 2a) and the resulting HLA-B27 open conformations (Fig. 4a). The evidence linking specific 
ERAP1 alleles with differences in the levels of HLA-B27 heavy chain open conformations is 
controversial. In one report, SpA-associated ERAP1 variants were associated with an increased 
production of HLA-B27 open conformations129. Protective ERAP1 variants were associated with 
reduced cell surface expression of class I heavy chains on cell lines and SpA patients’ cells129. In this 
study, gene silencing or pharmacologic inhibition of ERAP1 reduced the expression of HLA-B27 open 
conformations, reduced their binding to killer cell immunoglobulin-like immune receptors (KIR), and 
reduced T cell-mediated production of IL-17 in both in vitro and ex vivo experiments129. By contrast, in 
other studies, ERAP1 gene silencing and the expression of protective ERAP1 variants increased the cell 
surface expression of HLA-B27 open conformations and intracellular formation of HLA-B27 heavy 
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chains130,131. These observations highlight the difficulties with extrapolating data from cell lines 
overexpressing HLA-B27 to disease. As ERAP1 affects the supply of peptides to HLA-B27, differences 
in the expression of ERAP1 and HLA-B*27 genes in patients and experimental systems could contribute 
to these contradictory observations.  
Unlike peptide–HLA-B27 complexes, which interact with the TCR, HLA-B27 open conformations bind 
strongly to the inhibitory killer cell receptor, KIR3DL2, and leukocyte immunoglobulin-like receptor 
(LILR) family members, LILRB2 and LILRB5 132,133. HLA-B2705 protein forms more open 
conformations that bind to KIR and LILR than the non-disease-associated molecule, HLA-B2709134. 
KIR3DL2 is expressed on natural killer cells, γδ T cells and activated CD4+ and CD8+ αβ T cells135,136. 
KIR3DL2 also binds to other class I heavy chains, including HLA-F, which has also been linked to 
SpA137,138. However, KIR3DL2 binds more strongly to open conformations of HLA-B27 than to other 
HLA class I heavy chains139. LILRB2 and LILRB5 receptors that can bind HLA-B27 open conformations 
are expressed on monocytes and osteoclasts140-143. Thus, the binding of HLA-B27 open conformations 
to immune receptors probably affects the function of a diverse array of immune cells in SpA.  
The binding of KIR3DL2 to open conformations of HLA-B27 promotes the production of IL-17A by 
TH17  cells in vitro144. HLA-B27-positive patients with SpA have increased numbers of KIR3DL2-
positive TH17 cells and NK cells in their peripheral blood, peripheral joints and inflamed intestinal 
sites136,145. KIR3DL2-positive TH17 cells account for the majority of IL-23 receptor-expressing T cells in 
patients with SpA146. These cells also express markers of activated T cells and other markers that 
suggest migration from the intestine, and they show evidence of oligoclonal expansion144,146. Inhibiting 
the binding of KIR3DL2 to HLA-B27 open conformations on transfected cells and on cells that 
naturally express HLA-B27 both inhibits survival of activated T cells from patients with SpA and 
healthy controls in vitro and limits IL-17 production by patient T cells ex vivo 144,147. The binding of 
open conformations of HLA-B27 to KIR3DL2 on NK cells inhibits their production of IFNγ, potentially 
reducing an important brake on IL-17 production124,139,147. Because KIR3DL2 is an inhibitory receptor, 
KIR3DL2–HLA-B27 interactions would be expected to reduce activation signals in KIR3DL2-
expressing cells. T cell survival and differentiation depends on a balance between activating and 
inhibitory signals. Diminished T cell signalling, in TH17 cell differentiation cultures and in a mouse 
model of SpA, promotes the production of IL-17 and causes arthritis, in large part, by enhancing the 
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survival of autoreactive T cells and increasing the ratio of TH17 to TH1 cells148,149. Thus, the propensity 
of HLA-B27 to form open conformations seems to be linked to increased IL-17 production and an 
increased TH17–TH1 ratio, which have important functions in driving SpA pathogenesis. Hence, open 
B27 conformations might synergize with other factors promoting TH17 activity or limiting TH1 activity. 
The precise contribution of KIR3DL2 and LILR interactions with HLA-B27 open conformations to the 
differentiation of TH17 cells, osteoclasts and other immune subsets in SpA warrants further 
investigation.  
 
[H3] HLA-B27 misfolding, the unfolded protein response and autophagy 
HLA-B27-mediated activation of the unfolded protein response (UPR) to ER stress, and its putative 
contribution to arthritis, have been extensively reviewed elsewhere150. The free Cys67 and other 
molecular properties of HLA-B27 heavy chains promote HLA-B27 misfolding in the ER150. Inefficient 
intracellular disposal of misfolded molecules causes ER stress and promotes the production of 
inflammatory mediators through the induction of the UPR150,151. Misfolded proteins in the ER are 
disposed of by ER-associated degradation (ERAD). The slow assembly of peptide–HLA-B27 complexes 
predisposes the cell to increased levels of ER-associated degradation (ERAD), the induction of an UPR 
and autophagy, especially when HLA-B27 production is upregulated during inflammation150. Disease-
associated HLA-B27 subtypes oligomerize, accumulate in the ER more readily, and are more 
susceptible to ERAD than non-associated class HLA-B27 subtypes152-154. Increased sequestration of 
unfolded HLA-B27 by the ER chaperone BiP (immunoglobulin binding protein) increases the 
expression of UPR-related genes and pro-inflammatory immune genes, such as IL-23155. The UPR also 
promotes the production of IL-1α and IFNβ, which increase and inhibit TH17 cell differentiation, 
respectively. Autophagy, induced as a consequence of a UPR, also promotes IL-23 production.  
In HLA-B*27 transgenic rats, which express very high levels of HLA-B27, misfolded HLA-B27 drives the 
UPR in macrophages156 and is associated with increased osteoclast formation157. However, there are 
conflicting reports concerning whether the UPR is upregulated in mononuclear cells and macrophages 
from the synovial tissue of patients with SpA153,158,159. While an early study showed upregulation of BiP 
in mononuclear cells from peripheral joints of AS patients133,  a later study showed activated 
macrophages from patients with SpA produced more IL-23 than those from healthy individuals, but 
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without any notable upregulation of the UPR160. Other studies showed that while autophagy was 
increased without an ongoing UPR in the intestinal tissue of patients with SpA, autophagy was not 
upregulated in their peripheral blood or joints161,162. Disease-associated polymorphisms in ERAP1 are 
not correlated with ER stress in patients with AS163. Overall, further work is needed to distinguish the 
direct effects of HLA-B27 on ER stress and the UPR from effects occurring downstream of 
inflammation.  
 
[H3] HLA-B27 and the microbiome  
HLA-B27 biological effects could influence SpA pathogenesis by shaping the microbiome. HLA-B27 
promotes the survival of Gram-negative intracellular bacteria in transfected monocyte cell lines and in 
HeLa epitheloid cell lines expressing HLA-B27164,165. In vivo, any possible direct effects of HLA-B27 on 
the survival of microbes that promote arthritis are difficult to distinguish from the effects of an 
ineffective immune response. In HLA-B*27 transgenic rats, antibiotic administration inhibits osteoclast 
formation and attenuates arthritis166. HLA-B*27 transgenic rats have an increased susceptibility to 
Gram-negative intracellular bacterial infections, which could trigger development of SpA167,168. 
Perturbations in the intestinal microbiome in rodent and human SpA could be because of imbalances 
in type 1 and type 17 cytokine production169,170. A recent study in HLA-B*27 transgenic rats 
emphasizes the relationship between the host genetic background and associated changes in multiple 
microbes in establishing an inflammatory environment that promotes arthritis171. This area is 
currently under intense investigation in human studies. 
 
 
[H2] sJIA and HLA-DR 
In many inflammatory arthritides, the mechanisms underpinning HLA disease associations are less 
well-understood than in RA and SpA, especially where structural studies have not provided 
mechanistic clues, as exemplified by sJIA. GWAS data from patients of European ancestry identified a 
sJIA association with HLA-DRB1*11:04 and HLA-DRB1*11:01172. The researchers pinpointed a residue 
in the HLA-DR -chain, glutamic acid at position 68, that confers increased risk of sJIA; this residue 
does not interact directly with bound peptide. sJIA has many features of innate immune dysfunction, 
including systemic inflammation responsive to IL-1 and IL-6 inhibition173, and the absence of RF and 
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ACPA autoantibodies (as well as the absence of anti-nuclear antibodies in most patients)174. However, 
some evidence supports a contribution from CD4+ T cells to established sJIA175-178, and a subset of 
patients with sJIA develop chronic erosive arthritis without continued systemic features179. Thus, one 
model is that the initial phase of sJIA is dominated by innate immune activation and a subsequent 
phase is T cell dominant180. In this model, IL-1 driven development of TH17 cells is important for 
progression to the second (arthritic) phase181. In line with this model, the HLA-DRB1*11 association 
could reflect HLA-DR-restricted T cell responses in this second phase182. Alternatively, as cell surface 
HLA-DR binds superantigens, which then engage and activate T cells that express particular TCR Vβ 
families183, a HLA-DR–superantigen interaction could be preferentially promoted by the HLA-DRB1*11 
molecule184. Another possibility is that HLA-DR molecules could regulate innate immune responses in 
sJIA. For example, intracellular HLA-DR has been reported to influence Toll-like receptor signal 
strength in monocytes and dendritic cells185. An increased understanding of sJIA immunobiology is 
required to refine the mechanistic hypotheses on the association of HLA-DRB1*11 with this disease. 
 
[H1] Clinical implications  
[H2] Diagnosis and prognosis 
For diagnosis, even the strongest HLA associations are generally insufficient alone, because most 
people with risk alleles never develop the associated disease. However, strong HLA disease 
associations can sometimes contribute to a diagnosis. For example, identifying the presence of 
disease-associated HLA-B*27 alleles, and thus a risk of SpA, can aid the diagnostic evaluation of back 
pain186. Another potential clinical application of HLA typing is early identification of individuals at high 
arthritis risk among patients with psoriasis187188. One analysis identified glutamic acid at position 45 
(e.g., in the peptide binding groove of HLA-B*07, B*08, B*27, B*38 and B*39; Fig. 4b) as the critical risk 
factor associated with PsA in psoriasis patients116. A second analysis, with age of psoriasis onset 
considered as a covariate, found that the primary risk for PsA in psoriasis patients derives from 
asparagine (as found in HLA-B*27) or serine (in B*07 and B*08) residues at amino acid position 97 of 
HLA-B (Fig. 4b)117. The discrepancy between the two studies may reflect differences in the clinical 
subtypes between PsA cohorts in the two studies, as there is evidence that HLA-B allelic associations 
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may differ with PsA clinical phenotype189. Although mapping associations to amino acid residues is 
shedding light on PsA pathogenesis, in practice, screening of psoriasis patients for arthritis risk, if 
proven useful, is likely to employ simple typing for HLA-B*27 in the near term117. 
The scope for using HLA genetic data in diagnosis and prognosis might increase as patient genomic 
data become more widely available. Importantly, HLA allele associations are also being used as part of 
quantitative polygenic risk scores, which are scores based on weighted contributions of alleles at 
multiple gene loci. By including variation in multiple genes (HLA and non-HLA related genes; for 
example, >100 loci for RA190) and incorporating the effects of gene–gene interactions191,192, polygenic 
risk scores can improve the prediction of inherited susceptibility for complex genetic traits, such as 
rheumatic diseases. Their clinical use is generally not imminent, but holds promise for the future193. 
[H2] Disease subtypes  
Phenotypic subtypes of patients with the same clinical diagnosis can have distinct HLA associations, 
often with distinct autoantibody profiles. As discussed above, the most severe, erosive form of RA is 
associated both with HLA-DRB1 alleles that contain the SE33,58 and with seropositivity for RF, ACPA or 
anti-cyclic citrullinated peptide (anti-CCP) autoantibodies, although whether ACPAs are merely 
markers or active drivers of disease severity is unclear194. Among patients with RA, carriers of the 
DRB1 SE are also more responsive to DMARDs and some biologic therapeutics than non-carriers194,195. 
Interestingly, the protective effect of the HLA-DRB1*13 allele seems to be confined to ACPA-positive 
RA196. HLA-DR alleles are not always the primary risk factors for particular subgroup associations; for 
example, the HLA-DQB1*03:01 is associated with bronchiectatic airway disease and emphysema in RA, 
whereas HLA-DQB1*03:02 confers resistance to these conditions197,198. 
Additional examples of autoantibody-defined patient subsets with different associated HLA alleles 
include dermatomyositis and systemic sclerosis. In dermatomyositis, carriage of anti-Mi-2 (a nuclear 
antigen) antibodies is associated with HLA-DRB1*07:01, whereas carriage of anti-TIF1- (transcription 
intermediary factor 1) antibodies is associated with HLA-DQB1*02199. In systemic sclerosis, the two main 
serological patient subsets, defined by carriage of anti-centromere antibodies (anti-CA) or anti-
topoisomerase antibodies (anti-Topo I), also are distinguished by genetic differences at HLA class II 
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loci35,200: for example, DRB1*15:02 (anti-CA) and DRB1*16:02 (anti-Topo I) in the Han Chinese 
population200.  
HLA allelic associations can also support classification schemes built primarily on clinical 
phenotype. For example, In JIA, HLA class II allelic associations support the International League of 
Associations for Rheumatology (ILAR) classification of JIA subtypes201. Specifically, oligoarticular JIA 
(≤ 4 joints), RF-positive polyarticular JIA (≥ 5 joints), and systemic JIA are linked to different HLA 
alleles. Susceptibility alleles for oligoarticular JIA are HLA-DRB1*08, HLA-DRB1*11 and HLA-
DPB1*02:01202,203, for RF+ polyarticular JIA are DRB1 SE alleles204, and for systemic JIA, HLA-
DRB1*11:01 and HLA-DRB1*11:04172. The association of some HLA class II alleles with particular 
phenotypes in JIA provides support for the existence of particular clinical subtypes of JIA31. In 
addition, the overlap in HLA associations of oligoarticular JIA and RF-negative polyarticular JIA 
supports many analyses that have combined these two subgroups, which share early onset, female 
predominance and a high prevalence of antinuclear autoantibodies205. In 2017, HLA alleles were 
found to be shared between JIA subtypes and clinically similar types of adult inflammatory 
arthritis31. Notably, the HLA associations were stronger in the paediatric subtypes compared with 
their adult counterparts, consistent with a greater degree of heritability. Genetically and 
immunologically similar diseases in adults and children ultimately might be re-classified as the 
same disease206. HLA alleles will be instrumental in such classifications.  
[H2] Therapy 
No hypothesis linking particular HLA alleles to autoimmune or inflammatory mechanisms has been 
proven conclusively. However, in SE-positive RA and HLA-B*27-positive AS, therapeutic strategies 
based on mechanistic models might ultimately provide strong support for specific hypotheses (Fig 3, 
Fig 4, Supp. Fig. 2). For example, the model invoking shared epitope-containing allele-specific 
presentation of post-translationally modified peptides can be tested by developing inhibitors of 
PAD4207. Alternatively, a critical contribution of T cell responses to citrullinated peptides in RA 
pathogenesis would be supported if RA disease activity is curbed by therapeutic vaccination or a T cell 
therapy focused on these neoantigens. Encouraging preliminary findings have been reported for 
immunotherapy with tolerogenic dendritic cells presenting citrullinated peptides in patients with 
RA208. 
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In the HLA-B27 example, targeting TH17 cell-promoting cytokines or IL-17 has proven therapeutic 
efficacy in AS209,210, regardless of how HLA-B27 boosts TH17 cell immunity, whereas targeting IL-23, 
specifically induced via the HLA-B27 misfolding–UPR pathway in the ER (Fig. 4), has been 
ineffective211. If blocking KIR3DL2 or open conformations of HLA-B27 were efficacious in 
patients212,213, such a finding would strongly support a pathogenic function for this interaction. 
Moreover, although the exact function of ERAP1 in AS is unclear, the fact that ERAP1 variants with 
reduced activity are protective suggests that enzyme inhibitors could be beneficial214,215. Indeed, 
preliminary observations indicate that ERAP1 inhibitors limit the production of IL-17 by patient Th17 
cells ex vivo129.  
Furthermore, the shared HLA associations between adult and childhood RF-positive arthritis or in SpA 
provide a rationale for testing treatments in children that have efficacy in adults. The use of drugs 
targeting the IL-17 axis, currently in use in adults209,210 will probably become part of the 
armamentarium for HLA-B27-associated SpA in children and adolescents216. Any therapeutic benefit 
from such an approach would support the notion of shared disease mechanisms in children and adults. 
 
[H2] Prevention  
Studies have begun to elucidate how genetic and environmental factors combine to affect disease risk. 
Smoking57-59 and gingivitis60,61 are environmental risk factors for RA, but only in individuals who carry 
SE-containing HLA-DRB1 alleles. In principle, this knowledge enables the identification of at-risk 
individuals so that preventative approaches, such as smoking cessation and oral hygiene, can be 
personalized. Such genetically-targeted behavior modification could become an increasingly viable 
strategy as the cost of genotyping declines. Polygenic risk prediction models that incorporate 
environmental risk factors are being evaluated as an approach to tailor disease prevention 
strategies217. The prospect of reducing the possibility of chronic rheumatic disease might motivate 
individuals who are genetically at risk of disease to adhere to preventative measures.  
 
[H1] Conclusions 
Rheumatology has been at the forefront of understanding the genetic basis of complex autoimmune 
conditions. Accumulating data support the idea that HLA molecules contribute to disease through a 
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number of mechanisms, including the presentation of pathogenic neoantigens in RA and the 
production of pathogenic abnormal cell-surface HLA-B27 conformations in AS. The therapeutic 
promise of such mechanistic insights remains to be fully realised. Meanwhile, genetic data are 
increasingly becoming available to rheumatologists, patients and individuals at risk. Such information 
might aid diagnosis, disease stratification, and personalised treatment strategies. 
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Key points  
 The HLA gene complex is one of the best-studied regions of the human genome, and technical 
advances continue to deepen our understanding of its associations with inflammatory arthritis. 
 HLA genotypes corroborate distinct clinical and immunological subtypes between patients 
with the same clinical diagnosis or within the juvenile idiopathic arthritis umbrella.  
 HLA associations are helping to clarify mechanistic overlap between pediatric and adult forms 
of arthritis. 
 In some rheumatic conditions, potential mechanisms to explain HLA associations are 
emerging: shared epitope-dependent neoantigen presentation in ACPA-positive rheumatoid 
arthritis and HLA-B27 open conformations stimulating innate immune receptors in 
spondyloarthritis, among others. 
 HLA associations can provide adjuncts to diagnosis and prognosis of rheumatic conditions, and 
novel therapeutic and preventative approaches might develop from further mechanistic 
studies of these associations. 
 
 
Box 1. HLA gene polymorphism, nomenclature and typing techniques  
The mouse MHC, called H2, was recognized in the 1940s as a gene region that controls tumour 
transplant rejection218 (see George D. Snell’s Nobel Lecture). Its human homolog, the HLA complex on 
human chromosome 6p21.3, was first identified in the late 1950s using serological techniques22,71. 
Cloning of individual HLA genes and sequencing of HLA proteins culminated in the sequencing of the 
entire HLA gene region in 1999, ahead of the rest of the human genome22,219. The HLA region contains 
a dense cluster of immune-related genes (Fig. 1), of which the genes coding for classical 
transplantation antigens, i.e., the peptide-binding HLA class I and class II glycoproteins, exhibit the 
greatest allelic polymorphism. As a result, most individuals are heterozygous at most HLA class I and 
class II gene loci, and paternally-inherited and maternally-inherited allelic variants at these loci are co-
dominantly expressed. Thousands of alleles at several classical HLA class I and class II genes have been 
sequenced, and any two alleles typically differ at multiple nucleotide positions. 
There is a well-established nomenclature for HLA genes220 (see HLA System nomenclature for a 
detailed explanation and an annotated example). Letters (A, B and C for class I and DP, DQ and DR for 
class II) designate each locus; for class II genes, A and B suffixes (thus, DRA, DRB, etc.) are used to 
designate genes coding for the  and  chain polypeptide, respectively. Additional loci encoding 
alternate HLA-DR β-chains, which are present in some haplotypes, are numbered (e.g., DRB4). Locus 
names are followed by an asterisk and several pairs of digits, separated by colons, which identify the 
following types of allelic variation, in order: the major variants correlating with HLA serotypes; all 
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other coding variation; synonymous nucleotide substitutions in coding regions; noncoding differences 
including promoter polymorphisms. In practice, genotyping information may be incomplete, in which 
case unknown variation is omitted (thus, B*27:05 may have many non-coding subtypes, but this 
genotype states only the coding polymorphisms). A well-curated database of HLA gene, cDNA and 
protein sequences is the IPD-IMGT/HLA database221.  
HLA gene-encoded protein variants are commonly named without intervening asterisks and colons; 
we follow this convention here. Thus, the HLA-DRB1*04:01 allele codes for the -chain polypeptide of 
the HLA-DR0401 class II protein, and the HLA-B*27:05 allele codes for the heavy chain of the HLA-
B2705 class I protein. Any associated non-polymorphic chains, such as the HLA-DR or class I-
associated 2-microglobulin polypeptides are not specified: thus, for example, “DR0401 protein” refers 
to the heterodimer formed by the two polypeptide chains encoded by DRB1*04:01 and (non-
polymorphic) DRA*01:01 genes.  
In early studies, HLA types were primarily characterized using serotyping with panels of alloantisera, 
which contain antibodies specific for alleles that differ from that of the serum donor. These 
serologically distinct groups of alleles are still reflected in the 2-digit first number of the current allele 
nomenclature. For example, serotyping can distinguish B27 from B53 antigens using alloantisera, 
correlating with B*27 and B*53 genotypes, but is unable to distinguish the differences between B27:05 
and B27:03 gene variants. For clinical purposes, HLA typing is now performed by a combination of 
molecular and immunological techniques222. When microarrays are employed for genome-wide 
analysis of single-nucleotide polymorphisms (SNPs), HLA gene region SNPs together with data in 
reference panels can be used to infer a reasonably accurate HLA genotype by a process called 
imputation223 (for example, using the HLA-check tool, a software tool for imputation of HLA genotype 
from SNP data, and the genome-wide SNP database). Complete nucleotide sequencing is the gold 
standard for HLA genotyping; the technology continues to evolve224.  
 
Box 2: Function of MHC molecules  
 
The major immune function of MHC molecules is to enable T cells to detect host cells that have been 
exposed to infectious pathogens225. In such host cells, foreign proteins are degraded (processed) and 
the resultant peptides bind to MHC proteins, which are then displayed (presented) on the plasma 
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membrane, where they can activate T cells (Fig. 2). The T cell antigen receptor (TCR) interacts with 
parts of the peptide and parts of the MHC molecule (known as ‘dual recognition’)226-228.  
MHC class I  
MHC class I molecules (HLA-A, HLA-B and HLA-C in humans) acquire peptides derived from cytosolic 
protein degradation by the proteasome, transported by TAP transporters, and trimmed by ERAP (Fig. 
2a). The TAP1 and TAP2 subunits of the peptide transporter, and PSMB8 and PSMB9, two cytokine-
inducible proteasome subunits, are encoded in the HLA class II region (Fig. 1). In cells infected with 
cytosolic pathogens, pathogen-derived peptides enter the class I pathway and are presented to CD8+ T 
cells, which then kill the infected cells. In addition, MHC class I–self-peptide complexes on healthy host 
cells engage inhibitory receptors on natural killer (NK) cells, delivering signals that protect the healthy 
cells from NK cell-mediated attack229. Diminished MHC class I expression on stressed or infected cells 
removes this inhibition, making them more susceptible to NK cell-mediated cell death. 
MHC class II 
MHC class II molecules (HLA-DR, HLA-DQ and HLA-DP in humans) are constitutively expressed on 
professional antigen presenting cells (APCs; such as monocytes/macrophages, dendritic cells, and B 
lymphocytes), which take up pathogens or their products. MHC class II molecules acquire peptides 
derived from endocytic processing of these exogenous antigens (Fig. 2b) and present them to CD4+ T 
cells, which then activate or regulate effector responses through cell-surface interactions or cytokine 
release21. Endogenous  peptides present in endosomes (for example, derived from autophagy of 
cytosolic proteins) can also become bound to MHC class II molecules230. MHC class II  dimers are 
synthesised in the ER, associate with invariant chain (Ii), and are delivered to endosomes, where Ii is 
degraded by proteases. The subsequent release of residual class II-associated invariant chain peptides 
(CLIP) from the peptide-binding groove by HLA-DM creates MHC class II molecules competent for 
peptide loading (Fig. 2b).  HLA-DM and its inhibitor, HLA-DO, are also encoded in the MHC class II 
region (Fig. 1). 
Tolerance induction 
Importantly, MHC proteins are occupied by a diverse cargo of self-peptides (≥ 104 distinct species), 
arising from the physiological turnover of host proteins24,225,231. Presentation of these peptides to T 
cells by APCs in the thymus, including thymic epithelial cells, and at extra-thymic sites in the absence 
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of inflammation, induces T cell tolerance232, whether by T cell elimination (clonal deletion), anergy, or 
differentiation into regulatory T cells. 
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Legend to Figures 
 
Fig 1: Organization of the HLA gene region.  
The HLA gene region is shown with each bar representing a gene (simplified and not to scale). At the 
centromeric end (bottom) are 3 pairs of expressed genes coding for the  and  chains of classical 
class II molecules: HLA-DPA1, HLA-DPB1; HLA-DQA1, HLA -DQB1; and HLA-DRA, HLA-DRB1. HLA-DRB3, 
HLA-DRB4, or HLA-DRB5 (DRBx in the Figure) encode alternate expressed HLA-DR  chains in many 
haplotypes22,233. In the telomeric class I region (top), the HLA-A, HLA-C, and HLA-B genes code for 
classical class I heavy chains (also known as class Ia genes), which assemble with 2-microglobulin 
(encoded on chromosome 15). Classical class I and II genes display extraordinary allelic variation, 
except for HLA-DRA22. Interspersed among the class II loci are genes that regulate antigen 
presentation, such as TAP1 and TAP2 an PSMB8 and PSMB9, which function in the class I pathway, as 
well as genes for HLA-DM and HLA-DO, in the class II pathway85,225,234(explained in Box 2). The HLA 
class I region contains genes encoding ‘non-classical’ class Ib heavy chains, which are not involved in 
peptide presentation to CD8+ TCR+ T cells22. The class III region encodes non-polymorphic immune 
molecules that are not directly involved in antigen presentation (such as complement components and 
TNF). 
 
 
Fig. 2: MHC class I and class II proteins: maturation and function.  
 
Distinct accessory molecules enable MHC class I and class II molecules to acquire peptides from 
different locations21,225,234.  
a) MHC class I molecules acquire peptides from proteasome-mediated degradation of cytosolic 
proteins. These peptides are imported into the ER by the transporter associated with antigen 
presentation (TAP1/TAP2), trimmed by ER aminopeptidases (ERAP), and loaded onto nascent class I 
heavy chain/β2-microglobulin complexes associated with TAP, tapasin, and other components (not 
shown). Tapasin ensures selection of a stable class I-bound peptide repertoire by promoting peptide 
exchange. In the ER and Golgi apparatus, class I molecules may further associate with the tapasin-
related protein, TAPBPR, with consequences that are as yet unclear235. After transport to the cell 
surface, the MHC class I molecules present bound peptides to CD8+ T cells.  
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b) Nascent MHC class II molecules bind to the invariant chain (Ii) polypeptide in the endoplasmic 
reticulum (ER). After transport to endosomes, Ii is trimmed, leaving class II-associated Ii peptides 
(CLIP) in the peptide-binding groove. HLA-DM promotes the exchange of CLIP for peptides generated 
in the endocytic pathway, but HLA-DO can also bind to and inhibit HLA-DM. After transport to the cell 
surface, MHC class II molecules present bound peptides to CD4+ T cells.  
 
Fig. 3 Neoantigen formation and presentation in RA  
a) Left, Structure of the HLA-DR0401 peptide-binding site (PDB entry 4MCZ, top view)67, complexed 
with citrullinated vimentin peptide. Side chains of citrulline at the P4 position of the peptide are 
shown in light red; three -chain residues (V11, K71, A74) reported by Raychaudhuri et al.32 to explain 
RA association, in green; and the other residues in the 70-74 -chain region (the SE) in gold. Right, 
Neoantigen model. SE-containing HLA-DR variants present modified peptides with electrically neutral 
citrulline residues at P4, but they fail to present the unmodified parent peptides with positively-
charged arginine at P4. Consequences for tolerance are explained in the text. In patients with a SE-
containing HLA-DR allele, tolerogenic vaccination with citrullinated peptides might normal immune 
regulation (red arrow).  
b) Neoantigen formation by post-translational modification. Left, Peptidylarginine deiminases (PAD) 
mediate calcium-dependent citrullination of arginine residues on polypeptide chains (left). Right, in 
the presence of cyanate (generated by oxidation of thiocyanate by neutrophil myeloperoxidase (MPO) 
at sites of inflammation236), lysine residues are carbamylated to homocitrulline, which is identical to 
citrulline except for an extra methylene group73. Inhibition of neutrophil enzymes (red arrows) might 
disrupt the presentation of neoantigens that perpetuate autoimmunity. 
 
Fig. 4. Mechanisms of HLA-B*27 association with SpA  
a) Left, Misfolding of HLA-B27 in the endoplasmic reticulum (ER) leads to disposal by ER-associated 
degradation (ERAD) in the cytosol, and to ER stress, which synergizes with pro-inflammatory signals 
to favour IL-23 secretion, which, in turn, encourages pathogenic CD4+ T helper 17 (TH17) cell 
differentiation. Middle, Correctly-folded, cell surface HLA-B27–peptide complexes present 
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arthritogenic peptides and activate CD8+ T cells. Right, Endosomal turnover of folded HLA-B27 
complexes leads to the production of disulfide-bonded HLA-B27 heavy-chain dimers and other open 
conformations. The open conformations return to the plasma membrane and provide aberrant signals, 
e.g., via the NK cell receptor, KIR3DL2, to CD4+ Th17 cells. IL-17 and IL-23 signalling contributes to 
osteoclast development. Therapeutic targets (red arrows) might include IL-17 and IL-23 and their 
signalling pathways, KIR3DL2, and cell surface HLA-B27 open conformations.  
b) Structure of the peptide binding site of HLA-B2705 (PDB entry 2BST, top view)237. The cysteine at 
position 67 is implicated in the generation of open conformation heavy chain dimers. Residues 45 and 
97 (glutamate and asparagine, respectively, in B*27:05) are located within the binding groove and 
influence peptide binding118.  
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Table 1: Representative studies of HLA class I or class II susceptibility loci in RA and ASa 
HLA molecule Notable associated alleles or 
haplotypes  
Type Odds Ratio 
(95% CI) 
Population Ref. 
ACPA-positive rheumatoid arthritis 
HLA-DRB1 Shared epitope (SE) allelesb 
+/+ (homozygous) 
+/- (heterozygous) 
 
Risk alleles 
 
11.79 (6.58-21.13)   
4.37 (2.88–6.65) 
 
White  
(Dutch) 
 
238 
HLA-DRB1*01:01 SE Risk allele 1.38 (1.28-1.50) White 
(European) 
32c 
HLA-DRB1*04:01 
 
 
SE Risk allele 4.14 (3.86-4.44) White 
(European) 
32 
HLA-DRB1*04:04 SE Risk allele 3.17 (2.83-3.54) White 
(European) 
32 
HLA-DRB1*04:05 SE Risk allele 2.31 (1.77-3.01) White 
(European) 
32 
HLA-DRB1*04:05 SE Risk allele 3.4 (2.0-5.7) Japanese 239 
HLA-DRB1*04:05 SE Risk allele 3.93 (3.09-5.05) Korean 32 
HLA-DRB1*04:08 SE Risk allele 5.48 (4.11-7.30) White 
(European)  
32 
HLA-DRB1*09:01 Risk alleled
 
1.43 (1.11-1.85) Japanese 240 
HLA-DRB1*10:01 SE Risk allele 2.53 (2.04-3.14) White 
(European) 
32 
HLA-DRB1*14:02 SE Risk allele 2.38 (1.38-4.12) Indigenous North 
American 
241 
HLA-DRB1*13:01 Protective allele 0.24 (0.09-0.59) White 
(European) 
52 
HLA-DRB1*13:02 Protective allele 0.42 (0.31-0.58) Japanese 242 
Ankylosing spondylitis 
HLA-B27 HLA-B*27 
 
Risk allele 27.5 (10.8-72.1) 
 
Moroccan 
 
243 
HLA-B*27 Risk allele 81.4 (49.8-134.3) White  
(Dutch)  
101 
HLA-B*27 Risk allele 87.7 (66.8-115.0) White  
(US)  
244 
HLA-B*27 
 
Risk allele 120.8 (83.3-204.8) Taiwanese 100 
HLA-B*27:02 
 
Risk allele 43.4 (29.8-63.2) White (European 
descent) 
30 
HLA-B*27:04 
 
Risk allele 86.8 [na]e Chinese (Han) 
 
245 
HLA-B*27:05 
 
Risk allele 62.4 (56.9-68.4) 
 
White (European 
descent) 
30 
HLA-B40 HLA-B*40.01f 
 
Risk allele 1.8 (1.2-2.8) White  
(Dutch) 
101 
HLA-B*40:01f Risk allele 1.79 (1.29-2.49) 
 
Taiwanese 100 
HLA-B47 
 
HLA-B*47:01 Risk allele 2.35 (1.43–3.86) White (European 
descent) 
30 
HLA-B7 HLAB*07:02 Protective allele 0.82 (0.74–0.91) White (European 
descent) 
30 
HLA-B57 HLAB*57:01 Protective allele 0.75 (0.61–0.92) White (European 
descent) 
30 
a This table focuses on HLA-DRB1 alleles for RA and HLA-B alleles for AS. Both diseases have been shown to have 
associations with other HLA loci32,244. 
b Shared epitope alleles used in ref 238 analysis: DRB1*01:01, *01:02, *01:04, *04:01, *04:04, *04:05, *04:08, 
*04:13, *04:16, *10:01, *14:02. 
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c All data from reference 32 in this Table are extracted from Supplementary Table 3 of that paper.  
d OR shown is based on analysis of HLA-DRB1 alleles in all RA compared to healthy controls. Comparing ACPA+ to 
ACPA- RA patients, HLA-DRB1*09:01 OR=2.02 (1.48-2.75)240. This allele has the sequence 70-RRRAE-74 in the SE 
region. 
e B*2704 is more strongly associated with AS than B*2705 (OR = 2.5 (1.4–4.2) in Han Chinese245. 
f Meta-analysis of B*40:01 OR 2.2 (1.8-2.8). Epistatic effect: B27-positive/B40:01-neg a has relative risk (RR) of 69 
(40-111), B27-positive/B40:01-positive has RR of 342 (147-708)101. Results in a Taiwanese cohort are similar100. 
na, confidence interval not available 
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Glossary terms  
 
 
 
 Epistasis: the ability of one gene to influence the effect of another gene on a phenotype (such 
as the risk of developing a rheumatologic condition); also known as gene –gene interactions. 
 Haplotypes: a constellation of allelic variants at closely-linked loci, which are preferentially or 
exclusively inherited together owing to to linkage disequilibrium  
 Linkage disequilibrium: a lack of recombination within a stretch of DNA (relative to 
recombination frequencies expected on the basis of the length of DNA involved), such that 
allelic variants contained within that stretch are systematically co-inherited as a haplotype. 
 Neoantigen: An antigenic peptide that arises from the post-translational modification of a self-
protein, thus appearing foreign or new; the generation of such peptides is a proposed 
mechanism for breaking self-tolerance. 
 Polygenic risk score: a composite score based on weighted contributions of a large number of 
allelic variants across the genome to provide greater stratification of risk, especially at the tail 
ends of the risk distribution. 
 Polymorphism: variability, within a population, of a gene or a group of genes. In the HLA 
region, several types of polymorphism can be distinguished, including polygeny (the existence 
of multiple gene loci coding for polypeptides with similar functions), the presence of alternate 
HLA-DRB genes in some HLA-DRB1 haplotypes, and allelic variation.  
 
 
 
